2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-174443
    PROTAC sEH degrader-2 98%
    PROTAC sEH degrader-2 is a PROTAC targeting degradation agent for soluble epoxide hydrolase (sEH) with pIC50 values of the catalytic domain of 8.37 (human sEH-H) and 7.12 (mouce sEH-H). PROTAC sEH degrader-2 can be used for the research related to inflammation and neuroinflammation, such as Alzheimer's disease. (Structure Note: Pink: sEH-H ligand (HY-174225); Blue: CRBN Ligand (HY-103597); Black: linker; E3 + linker (HY-141011))
    PROTAC sEH degrader-2
  • HY-174449
    HDAC6-IN-62 3056725-89-1
    HDAC6-IN-62 (Compound 2.12) is a selective HDAC6 inhibitor, with an IC50 value of 0.25 nM. HDAC6-IN-62 can be used in the research of Charcot-Marie-Tooth disease.
    HDAC6-IN-62
  • HY-174462
    AChE-IN-90 98%
    AChE-IN-90 (Compound 5b) is an orally active, brain-penetrant and potent acetylcholinesterase (AChE) inhibitor with an IC50 value of 0.023 μM against human AChE and lower selectivity for butyrylcholinesterase (BuChE) (IC50 1.8 μM). AChE-IN-90 increases acetylcholine levels in the synaptic cleft. AChE-IN-90 is promising for research of neurodegenerative diseases such as Alzheimer's disease.
    AChE-IN-90
  • HY-174464
    AChE/BChE-IN-28
    AChE/BChE-IN-28 (Compound 5q) is a BChE inhibitor with an IC50 of 13.49 μM. AChE/BChE-IN-28 also exerts moderate inhibitory effect on AChE, with an IC50 of 35.23 μM. AChE/BChE-IN-28 can be used in the research of Alzheimer's disease.
    AChE/BChE-IN-28
  • HY-174466
    5-HT2AR ligand 1 98%
    5-HT2AR ligand 1 (Compound 2 cis) is a 5-HT2AR ligand with nanomolar affinity for 5-HT2AR (Ki: 32 nM). 5-HT2AR ligand 1 is capable of inducing β-arrestin 2 recruitment. 5-HT2AR ligand 1 can be used in the research of neurological diseases.
    5-HT2AR ligand 1
  • HY-17447B
    (1S,2R)-Tranylcypromine hydrochloride 4548-34-9 98%
    (1S,2R)-Tranylcypromine ((1S,2R)-SKF 385) hydrochloride is a potent antidepressant agent. (1S,2R)-Tranylcypromine hydrochloride can inhibits MAO and LSD1.
    (1S,2R)-Tranylcypromine hydrochloride
  • HY-174817
    NOX5-IN-1 98%
    NOX5-IN-1 (Compound 13) is a selective NADPH oxidase 5 (NOX5) inhibitor with an IC50s of 0.30  μM. NOX5-IN-1 significantly inhibits NOX5-dependent production of ROS in freestyle293 cells (EC50: 0.86  μM). NOX5-IN-1 can be used for NOXs related diseases research, such as cardiovascular, cancer and neuroinflammation.
    NOX5-IN-1
  • HY-174818
    NOX5-IN-2 98%
    NOX5-IN-2 (Compound 17) is a selective NADPH oxidase 5 (NOX5) inhibitor with an IC50s of 0.70  μM. NOX5-IN-2 significantly inhibits NOX5-dependent production of ROS in freestyle293 cells (EC50: 1.8  μM). NOX5-IN-2 can be used for NOXs related diseases research, such as cardiovascular, cancer and neuroinflammation.
    NOX5-IN-2
  • HY-174833
    MAO-A-IN-2 1627618-37-4
    MAO-A-IN-2 (Compound 4l) is a selective monoamine oxidase A (MAO-A) inhibitor with an IC50 value of 0.4 μM. MAO-A-IN-2 reduces the degradation of monoamine neurotransmitters (e.g., serotonin, norepinephrine). MAO-A-IN-2 is promising for research of neurological diseases related to monoamine neurotransmitter imbalance such as depression and anxiety disorders.
    MAO-A-IN-2
  • HY-174834
    MAO-B-IN-44 1454707-25-5
    MAO-B-IN-44 (Compound 4n) is a selective monoamine oxidase B (MAO-B) inhibitor targetin with an IC50 value of 1.01 μM, showing weak inhibition on MAO-A (IC50=14.4 μM). MAO-B-IN-44 reduces degradation of neurotransmitters like dopamine. MAO-B-IN-44 is promising for research of neurodegenerative diseases related to MAO-B abnormalities such as Parkinson’s disease.
    MAO-B-IN-44
  • HY-174838
    CB1-IN-3
    CB1-IN-3 (Compound 6i) is a potent cannabinoid type 1 receptor (CB1) inhibitor. CB1-IN-3 is promising for research of obesity, inflammation, and neurological diseases.
    CB1-IN-3
  • HY-174845
    Nav1.8-IN-20 3024470-62-7
    Nav1.8-IN-20 (Compound I) is an orally active and potent voltage-gated sodium channel Nav1.8 inhibitor with an IC50 value of 14 nM. Nav1.8-IN-20 blocks the generation and conduction of action potentials in peripheral nociceptive neurons, exerting analgesic effects. Nav1.8-IN-20 is promising for research of various pain types such as acute pain, chronic pain, inflammatory pain, and neuropathic pain.
    Nav1.8-IN-20
  • HY-174846
    TRPM8 antagonist 4 prodrug 98%
    TRPM8 antagonist 4 prodrug (Compound 8b) is an orally active CB2R agonist (EC50: 51.2 nM) and a weak TRPM8 antagonist. TRPM8 antagonist 4 prodrug is a prodrug of TRPM8 antagonist 4 (HY-174825). TRPM8 antagonist 4 prodrug exhibits anti-inflammatory and analgesic activities and can be used in the research of inflammation-related pain disorders.
    TRPM8 antagonist 4 prodrug
  • HY-174848
    PQM-244 316139-50-1
    PQM-244 (Compound 5c) is an orally active and multi-target modulator of TRPV1 and CB1 and CB2 receptors. PQM-244 has significant peripheral antinociceptive effects on both neurogenic and inflammatory phases. PQM-244 also has potential antioxidant activity with an IC50  of  14.15 µM for radical scavenging DPPH. PQM-244 can be used for chronic pain and inflammatory disease research, such as diabetes, atherosclerosis and Alzheimer’s disease.
    PQM-244
  • HY-174898
    5-HT2C agonist-9 2873459-44-8
    5-HT2C agonist-9 (Compound 33) is a 5-HT2C agonist with an EC50 of 1.4 nM for h5-HT2C. 5-HT2C agonist-9 can be used in the research of diseases such as depression, drug addiction, alcoholism, PTSD and neuropathic pain.
    5-HT2C agonist-9
  • HY-174899
    AMPA-IN-2 75828-06-7 98%
    AMPA-IN-2 is an orally active AMPA inhibitor that can cross the blood-brain barrier. AMPA-IN-2 improves epileptic seizures by inhibiting the intrinsic excitability of neurons and inhibiting the excitability of glutamatergic transmission. AMPA-IN-2 exerts anti-epileptic effects in the pentylenetetrazol (PTZ) model and can be used as a promising candidates with high broad-spectrum anti-epileptic potential.
    AMPA-IN-2
  • HY-174909
    5-HT2A receptor agonist-11 3088416-38-7
    5-HT2A receptor agonist-11 (Compound I-69) is a 5-HT2A receptor agonist with an EC50 of 22 nM. 5-HT2A receptor agonist-11 can be used in the research of mental illness or central nervous system disorders.
    5-HT2A receptor agonist-11
  • HY-174923
    AZ12943203 98%
    AZ12943203 (Compound 13e) is a GSK-3 PET radioligand with a Kd of 2.94  nM. AZ12943203 has a significant inhibitory potency toward GSK-3β (IC50 : 4.44 nM), and can specifically bind to GSK-3-rich regions of the rodent brain. AZ12943203 can be used for neurodegenerative diseases imaging, particularly Alzheimer’s disease.
    AZ12943203
  • HY-17493A
    MI-773 TFA 1303609-37-1 98.91%
    MI-773 TFA is an orally active, selective MDM2-p53 interaction inhibitor with a Ki of 0.88 nM for MDM2. MI-773 TFA blocks the MDM2-TP53 interaction. MI-773 TFA potently activates p53. MI-773 TFA induces Apoptosis. MI-773 TFA causes tumor regression in xenograft models of adenoid cystic carcinoma. MI-773 TFA exhibits anticancer effects in neuroblastoma. MI-773 TFA can be used for the research of adenoid cystic carcinoma.
    MI-773 TFA
  • HY-174977
    P2Y12R ligand-1
    P2Y12R ligand-1 (Compound 41) is a high-affinity P2Y12R ligand with a Ki value of 17.1 nM. P2Y12R ligand-1 labeled with [18F] can be used in studies of brain PET imaging.
    P2Y12R ligand-1
Cat. No. Product Name / Synonyms Application Reactivity